A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Head and neck cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms iNSITE-2
  • Sponsors BIND Therapeutics
  • Most Recent Events

    • 06 Apr 2016 According to a BIND Therapeutics media release, based on the results of this trial, the company decided to halt further enrollment of patients with advanced cervical and head and neck cancers.
    • 06 Apr 2016 Status changed from recruiting to discontinued, according to a Bind Therapeutics media release.
    • 06 Apr 2016 Results published in a Bind Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top